27 November 2024
Ziccum CEO Ann Gidner gave a compelling presentation at Stora Aktiedagarna, Stockholm on 27th of November showcasing Ziccum’s groundbreaking LaminarPace technology.
21 November 2024
On November 21st in Lund, Ziccum CEO Ann Gidner delivered an engaging presentation at BioStock Life Science Summit, highlighting the innovative LaminarPace technology, which garnered significant interest from investors and life science experts.
12 September 2024
Ziccum CEO Ann Gidner shared insights in an interview at BioStock Investing in Life Science: From Seed to Success, held in Stockholm on September 12th, 2024, discussing the groundbreaking LaminarPace technology that fully unlocks the potential of mRNA.
12 September 2024
On September 12th in Stockholm, Ziccum CEO Ann Gidner delivered a compelling presentation at BioStock Investing in Life Science: From Seed to Success, garnering strong interest from life science leaders and investors.
30 May 2024
Ziccum’s CEO Ann Gidner delivered a presentation at BioStock 2024 Global Forum on May 30th, 2024 in Lund, Sweden, outlining the disruptive potential of LaminarPaceTM, a formulation and drying technology for delicate liquid biologics.
12 March 2024
Ziccum CEO Ann Gidner presented in Swedish to investors at Stockholm Corporate Finance’s Life Science Capitals Markets Day. Watch the entire presentation with full slideshow, in Swedish, here: https://ir.financialhearings.com/stockholm-corporate-finance-cmd-2024-12-mars-ziccum?seek=87
12 February 2024
Ziccum released its CEO Fireside Chat on mRNA development hosted by US Force Family Office and with CEO Ann Gidner. The discussion included the valuable participation of Dr Romain Micol, CEO and co-founder of Combined Therapeutics; a privately held Boston-based biotechnology company developing the next generation of high value mRNA vaccines. Dr Micol shared his insights in the field and his appreciation for the LaminarPace technology, as a Key Opinion Leader for mRNA development. The event was hosted by Force Family Office, in the Force for Knowledge series and was moderated by Steven Saltzstein, CEO of Force.
31 January 2024
Watch Ziccum CEO Ann Gidner in a new video interview in Swedish with Eucaps analyst Jonathan Furelid. She shares insights on the company's new mRNA results, participation in the mRNA Summit and funding with its new US investor.
8 November 2023
Watch Ziccum CEO Ann Gidner in an exclusive new video interview with Eucaps analyst Jonathan Furelid. It provides insights and analysis of Ziccum’s new Evaluation Agreement, its third in six months, plus the company’s Q3 2023 highlights.
29 August 2023
In part two of her Analyst interview CEO Ann Gidner offers a deep dive into the second of the company’s recent milestone Feasibility agreements plus an analysis of mRNA, why it is generating such historic levels of investment, and how Ziccum’s unique drying technology LaminarPace could be a key enabler in unlocking its potential.
25 August 2023
With two paid Evaluation agreements signed with world-leading mRNA partners, after having proven the LaminarPace technology for mRNA/LNP treatment, Q2 2023 was the most successful in Ziccum’s history. CEO Ann Gidner describes the company’s road ahead in the first of two CEO interviews.
“We’re drying biologics” – watch Ziccum CEO Ann Gidner present Ziccum and LaminarPace – our unique ambient drying technology for biopharmaceuticals – at BioStock Life Science Fall Summit 2022.